Diagnostic and therapeutic care pathway for fibromyalgia

Early diagnosis and timely and appropriate treatments positively influence the history of fibromyalgia syndrome (FM), with favourable repercussions at clinical, psychological, social and economic levels. Notwithstanding, there are still significant problems with timeliness of diagnosis, access to pharmacological therapies - particularly to innovative ones - and appropriate and effective taking in charge of patients. All the aforementioned factors have a great impact on FM patients' quality of life. Indeed, even though the World Health Organisation recognised FM as a chronic condition in the International Classification of Diseases 10th edition (ICD-10), many countries still fail to recognise the syndrome, and this negatively influences the capability to appropriately protect and care for patients. This is the case in several European Countries. In Italy, a few Regions have started to put in place precise indications for people suffering from FM, aiming at the implementation of diagnostic-therapeutic pathways. The Diagnostic-Therapeutic Care Pathway (DTCP) provides an important tool to meet the needs of patients suffering from chronic diseases. They present the organisation of an integrated assistance network. This includes a seamless path for disease prevention, diagnosis and treatment, by means of cooperation among physicians and other healthcare professionals

Fibromyalgia position paper

Fibromyalgia syndrome is one of the most common causes of chronic widespread pain, but pain accompanies a wide range of ancillary symptoms. To date, its aetiopathogenesis remains elusive, and diagnosis is exquisitely clinical, due to the lack of biomarkers or specific laboratory alterations in fibromyalgia patients. This position paper has the purpose to summarise the current scientific knowledge and expert opinions about the main controversies regarding fibromyalgia syndrome, namely: (i) fibromyalgia definition and why it is still not recognised in many countries as a distinct clinical entity; (ii) fibromyalgia severity and how to evaluate treatment outcome; (iii) how to treat fibromyalgia and which is a correct approach to fibromyalgia patients

Fibromyalgia position paper

none27siFibromyalgia syndrome is one of the most common causes of chronic widespread pain, but pain accompanies a wide range of ancillary symptoms. To date, its aetiopathogenesis remains elusive, and diagnosis is exquisitely clinical, due to the lack of biomarkers or specific laboratory alterations in fibromyalgia patients. This position paper has the purpose to summarise the current scientific knowledge and expert opinions about the main controversies regarding fibromyalgia syndrome, namely: (i) fibromyalgia definition and why it is still not recognised in many countries as a distinct clinical entity; (ii) fibromyalgia severity and how to evaluate treatment outcome; (iii) how to treat fibromyalgia and which is a correct approach to fibromyalgia patients.noneSarzi-Puttini, Piercarlo; Giorgi, Valeria; Atzeni, Fabiola; Gorla, Roberto; Kosek, Eva; Choy, Ernest H; Bazzichi, Laura; Hauser, Winfred; Ablin, Jacob N; Aloush, Valerie; Buskila, Dan; Amital, Howard; Da Silva, Jose A P; Perrot, Serge; Morlion, Bart; Polati, Enrico; Schweiger, Vittorio; Coaccioli, Stefano; Varrassi, Giustino; Di Franco, Manuela; Torta, Riccardo; Øien Forseth, Karin Maria; Mannerkorpi, Kaisa; Salaffi, Fausto; Di Carlo, Marco; Cassisi, Gianniantonio; Batticciotto, AlbertoSarzi-Puttini, Piercarlo; Giorgi, Valeria; Atzeni, Fabiola; Gorla, Roberto; Kosek, Eva; Choy, Ernest H; Bazzichi, Laura; Hauser, Winfred; Ablin, Jacob N; Aloush, Valerie; Buskila, Dan; Amital, Howard; Da Silva, Jose A P; Perrot, Serge; Morlion, Bart; Polati, Enrico; Schweiger, Vittorio; Coaccioli, Stefano; Varrassi, Giustino; Di Franco, Manuela; Torta, Riccardo; Øien Forseth, Karin Maria; Mannerkorpi, Kaisa; Salaffi, Fausto; Di Carlo, Marco; Cassisi, Gianniantonio; Batticciotto, Albert

Diagnostic and therapeutic care pathway for fibromyalgia

Early diagnosis and timely and appropriate treatments positively influence the history of fibromyalgia syndrome (FM), with favourable repercussions at clinical, psychological, social and economic levels. Notwithstanding, there are still significant problems with timeliness of diagnosis, access to pharmacological therapies - particularly to innovative ones - and appropriate and effective taking in charge of patients. All the aforementioned factors have a great impact on FM patients' quality of life. Indeed, even though the World Health Organisation recognised FM as a chronic condition in the International Classification of Diseases 10th edition (ICD-10), many countries still fail to recognise the syndrome, and this negatively influences the capability to appropriately protect and care for patients. This is the case in several European Countries. In Italy, a few Regions have started to put in place precise indications for people suffering from FM, aiming at the implementation of diagnostic-therapeutic pathways. The Diagnostic-Therapeutic Care Pathway (DTCP) provides an important tool to meet the needs of patients suffering from chronic diseases. They present the organisation of an integrated assistance network. This includes a seamless path for disease prevention, diagnosis and treatment, by means of cooperation among physicians and other healthcare professionals